- Home
- CCEL vs LSB Comparison
CCEL vs LSB Comparison
Compare CCEL & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- LSB
- Stock Information
- Founded
- CCEL 1989
- LSB 2002
- Country
- CCEL United States
- LSB China
- Employees
- CCEL N/A
- LSB N/A
- Industry
- CCEL Managed Health Care
- LSB
- Sector
- CCEL Health Care
- LSB
- Exchange
- CCEL Nasdaq
- LSB NYSE
- Market Cap
- CCEL 50.0M
- LSB 53.6M
- IPO Year
- CCEL 1997
- LSB N/A
- Fundamental
- Price
- CCEL $7.71
- LSB $2.23
- Analyst Decision
- CCEL
- LSB
- Analyst Count
- CCEL 0
- LSB 0
- Target Price
- CCEL N/A
- LSB N/A
- AVG Volume (30 Days)
- CCEL 15.6K
- LSB 7.4K
- Earning Date
- CCEL 04-14-2025
- LSB 12-19-2024
- Dividend Yield
- CCEL 3.24%
- LSB N/A
- EPS Growth
- CCEL N/A
- LSB N/A
- EPS
- CCEL N/A
- LSB N/A
- Revenue
- CCEL $31,838,476.00
- LSB $79,415,311.00
- Revenue This Year
- CCEL $3.97
- LSB $39.33
- Revenue Next Year
- CCEL $0.91
- LSB $75.61
- P/E Ratio
- CCEL N/A
- LSB N/A
- Revenue Growth
- CCEL 1.95
- LSB N/A
- 52 Week Low
- CCEL $4.47
- LSB $1.88
- 52 Week High
- CCEL $9.50
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- CCEL 48.98
- LSB 40.56
- Support Level
- CCEL $7.26
- LSB $2.10
- Resistance Level
- CCEL $8.20
- LSB $2.49
- Average True Range (ATR)
- CCEL 0.54
- LSB 0.22
- MACD
- CCEL -0.02
- LSB 0.00
- Stochastic Oscillator
- CCEL 34.15
- LSB 16.35
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.